SCHEMBL17487557

SCHEMBL17487557

CCCc1ccc(CCc2ccc(-c3cc(F)c(F)c(F)c3)c(F)c2F)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSL P07711 1/20 0.36
CTSS P25774 1/20 0.36
CTSK P43235 1/20 0.36
CNR1 P21554 1/20 0.34
CNR2 P34972 1/20 0.34
RARB P10826 3/20 0.34
ALOX5 P09917 1/20 0.34
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
RARA P10276 1/20 0.33
RARG P13631 1/20 0.33
CHKA P35790 1/20 0.33
TP53 P04637 1/20 0.33
PKM P14618 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HSD17B10 Q99714 1/20 0.33
MPL P40238 2/20 0.33
LPL P06858 1/20 0.32
LIPG Q9Y5X9 1/20 0.32
HTR2A P28223 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17487870 0.92 RARB (0.40) CTSLCTSSCTSKCNR1CNR2
SCHEMBL17487368 0.91 RARB (0.38) CTSLCTSSCTSKCNR1CNR2
SCHEMBL17487893 0.90 ALOX5 (0.36) CTSLCTSSCTSKCNR1CNR2
SCHEMBL17487687 0.90 RARB (0.37) CTSLCTSSCTSKCNR1CNR2
SCHEMBL17487674 0.90 RARB (0.37) CTSLCTSSCTSKCNR1CNR2
SCHEMBL17487785 0.89 RARB (0.34) CTSLCTSSCTSKRARBALOX5
SCHEMBL17356554 0.89 CTSL (0.43) CTSLCTSSCTSKALOX5CHKA
SCHEMBL17487932 0.88 RARB (0.41) CTSLCTSSCTSKRARBALOX5
SCHEMBL9486644 0.87 CHKA (0.42) CTSLCTSSCTSKCNR1CNR2
SCHEMBL17487628 0.87 ALOX5 (0.36) CTSLCTSSCTSKCNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9441161-B2 Liquid crystal compound, liquid crystal composition and liquid crystal display device JNC CORPORATION (JP) 2016-09-13 US disclosed
US-9441161-B2 Liquid crystal compound, liquid crystal composition and liquid crystal display device JNC CORPORATION (JP) 2016-09-13 US disclosed
US-20160032187-A1 LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC PETROCHEMICAL CORPORATION (JP) 2016-02-04 US disclosed
US-20160032187-A1 LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC PETROCHEMICAL CORPORATION (JP) 2016-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160032187-A1 LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE OCIAD1, OCIAD2, PIEZO1 CTSL 2714/4885CTSS 2644/4885CTSK 2692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.